Generic Reviews Steaming Ahead, But Are Storm Clouds On The Horizon?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's generic office director notes a jump in year-end submissions – and a jump in refuse-to-receive actions.
You may also be interested in...
US FDA Outlines Internal ANDA Refuse-To-Receive Policy
Manual of Policies and Procedures document should provide more help to sponsors on what items must be in an ANDA for it to be reviewed.
US FDA Outlines Internal ANDA Refuse-To-Receive Policy
Manual of Policies and Procedures document should provide more help to sponsors on what items must be in an ANDA for it to be reviewed.
ANDA Stress Test: End-Of-Year Submission Bolus Pressures US FDA Review System
As more generic applications arrive, Office of Generic Drugs staff may have a tougher time reaching review goals.